Report from World Conference on Hair Research 2015 in Miami, USA
Follicum report from World Conference on Hair Research, November 18-21, 2015 in Miami, USA by CEO Jan Alenfall.
The 2015 WCHR Scientific meeting has the overall goal of presenting new research, sharing experiences, and discussing the advancement and knowledge of hair growth as well as skin-, hair- and scalp diseases. In addition it is a great overview of the therapeutic possibilities in hair related treatments and future opportunities. The following is a brief summary of the meeting.
Over 700 people from 53 countries attended, embodying a diverse international representation of committed scientists and clinicians in hair and skin research. Only a handful of new targets and drug mechanisms of action were presented and the meeting provided Follicum with an excellent opportunity to present interim data from our preclinical studies which are being performed in Germany and Israel.
Our collaborators were given the opportunity, not only to present a poster but also deliver an oral presentation. The poster session was very busy and attracted many visitors which resulted in a number of interesting discussions. The oral presentation at the seminar was well presented and gratifyingly received by the audience
During the event our scientific advisory board (SAB) also gathered for a meeting. We elected new members to the SAB and are gratified that so many distinguished scientists are on the board. We are now looking forward to fruitful collaborations and future meetings.
In summary, the poster we presented and the oral lecture were highly acknowledged by the audience, and we made a number of new and important contacts that may have a significant impact on the future development of Follicum. In addition, we identified several interesting opportunities that we will be following-up.
Jan Alenfall, CEO Follicum AB
For further information about Follicum, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 46-19 21 97
About Follicum AB
Follicum focuses on the development of the drug candidate FOL-005 which in preclinical studies has both stimulated and inhibited hair growth effectively even at low doses. The company's objective is to generate returns and revenues to other future projects through a sale or licensing of FOL-005 after a successful phase I / IIa study.